Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

 

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
R

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet Therapy vs. Quadruplet Therapy

By Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Rachid Baz
By Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Rachid Baz
105 views
February 14, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

19:39
Pfizer Hematology

The First Treatment Choice Matters

Feat. A. Ip
Videos
38:56

Moffitt Cancer Center Debate on the Use of MRD to Guide Transplant D…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

H. Fernandez, N. Bejanyan

224 views
31:09

2022 Updates on BCMA CAR T-Cell for MM: Real World Experience and Fu…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

M. Alsina

149 views
26:02

2022 Novel Immune-Based Therapy for R/R MM: Interactive Case Discuss…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

J. Brayer

206 views
16:00

Moffitt Cancer Center Debate: How Much Is Too Much in NDMM - Triplet…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

R. Baz

105 views
18:44

Moffitt Cancer Center Debate: How Much Is Enough in NDMM - Triplet T…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

K. Shain

161 views
20:54

2022 Updates on COVID-19 in Cancer Patients: Outcomes and Prevention

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

A. Giuliano

25 views
19:36

Managing Hematologic Toxicities From Immunotherapeutic Agents

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

M. Jaglal

295 views
23:05

Evaluation of Clonal Hematopoiesis in Patients With Solid Tumors: Ca…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

E. Padron

155 views
22:37

2022 Moffitt Cancer Center Updates on the Role of CAR T-Cells in Lym…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

F. Locke

102 views
26:22

2022 State of the Art: Best Frontline Therapy for CLL

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

J. Pinilla-Ibarz

562 views
25:53

Moffitt Cancer Center's Updates on Treatment of R/R DLBCL: Interacti…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

S. Gaballa

116 views
34:29

Moffitt Cancer Center Debate: Should NGS Be Reported in All Newly Di…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

B. Shah, H. Saeed

82 views
27:27

2022 State of the Art Frontline Management of the HR-MDS

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

R. Komrokji

347 views
22:48

Using Molecular Monitoring to Guide Therapy in AML: Interactive Case…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

K. Sweet

116 views